Clinical Trial Update: Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301) [Phase 3]

View source ↗

Summary

Phase 3 trial LASER301 evaluated YH25448 (Lazertinib) as first-line therapy for EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• YH25448 (Lazertinib) (Lazertinib)

Snippet

Sponsor: Yuhan Corporation | Conditions: Non-Small Cell Lung Cancer | Phase 3 | Status: COMPLETED | Results posted: 2024-03-22